

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: <https://orca.cardiff.ac.uk/id/eprint/116939/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Niarchou, Maria , Chawner, Samuel J.R.A., Doherty, Joanne L., Maillard, Anne M., Jacquemont, Sbastien, Chung, Wendy K., Green-Snyder, LeeAnne, Bernier, Raphael A., Goin-Kochel, Robin P., Hanson, Ellen, Linden, David E. J. , Linden, Stefanie C. , Raymond, F. Lucy, Skuse, David, Hall, Jeremy , Owen, Michael J. and Van Den Bree, Marianne B. M. 2019. Psychiatric disorders in children with 16p11.2 deletion and duplication. *Translational Psychiatry* 10.1038/s41398-018-0339-8

Publishers page: <https://doi.org/10.1038/s41398-018-0339-8>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See <http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



**Title: Psychiatric disorders in children with 16p11.2 deletion and duplication.**

**Running title: Psychopathology in 16p11.2 deletion/duplication**

Maria Nearchou PhD<sup>1,2,3</sup>, Samuel J.R.A. Chawner PhD<sup>1</sup>, Joanne L. Doherty MRCPsych<sup>1</sup>, Anne M. Maillard PhD<sup>4</sup>, Sébastien Jacquemont PhD<sup>5</sup>, Wendy K. Chung PhD<sup>6</sup>, LeeAnne Green-Snyder, PhD<sup>7</sup>, Raphael A. Bernier, PhD<sup>8</sup>, Robin P. Goin-Kochel, PhD<sup>9</sup>, Ellen Hanson, PhD<sup>10</sup>, David E. Linden PhD<sup>1</sup>, Stefanie Linden PhD<sup>1</sup>, F. Lucy Raymond M FRCP<sup>11</sup>, David Skuse MRCPsych<sup>12</sup>, Jeremy Hall PhD<sup>1</sup>, Michael J. Owen PhD<sup>1</sup>, van den Bree M.B.M. PhD<sup>1</sup>

<sup>1</sup>Medical Research Council Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, United Kingdom.

<sup>2</sup>Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia

<sup>3</sup>Department of Psychiatry, Neuropsychiatry Section, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

<sup>4</sup>Centre Cantonal Autisme, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Switzerland

<sup>5</sup>Service de Génétique Médicale, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

<sup>6</sup>Departments of Pediatrics and Medicine, Columbia University, New York, New York, USA

<sup>7</sup>Simons Foundation, New York, New York, USA

<sup>8</sup>Department of Psychiatry, University of Washington, Seattle, WA, USA

<sup>9</sup>Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA

<sup>10</sup>Divisions of Developmental Medicine and Psychiatry, Children's Hospital Boston, Massachusetts, USA

<sup>11</sup>Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK

<sup>12</sup>Behavioural and Brain Sciences Unit, Institute of Child Health, 30 Guilford Street,  
London WC1N 1EH, UK

**Corresponding Author:** Maria Niarchou, MRC Centre for Neuropsychiatric Genetics  
and Genomics, Cardiff University, Cathays, Maindy Road, Hadyr Ellis Building, second  
floor, Cardiff CF24 4HQ; Phone: +44 029 206 88355, Fax: 029 206 87915, E-mail:  
niarchoum@cardiff.ac.uk.

## **Abstract**

Deletion and duplication of 16p11.2 (BP4-BP5) have been associated with increased risk of intellectual disability and psychiatric disorder. This is the first study to compare the frequency of a broad spectrum of psychiatric disorders in children with 16p11.2 deletion and duplication. We aimed to evaluate 1) the nature and prevalence of psychopathology associated with copy number variation (CNV) in children with 16p11.2 by comparing deletion and duplication carriers with family controls; 2) whether deletion and duplication carriers differ in frequency of psychopathology. 217 deletion carriers, 77 deletion family controls, 114 duplication carriers and 32 duplication family controls participated in the study. Measures included standardized research diagnostic instruments. Deletion carriers had a higher frequency of any psychiatric disorder (OR= 8.9,  $p < 0.001$ ), Attention Deficit Hyperactivity Disorder (ADHD) (OR=4.0,  $p = 0.01$ ) and Autism Spectrum Disorder (ASD) (OR=39.9,  $p = 0.01$ ) than controls. Duplication carriers had higher frequency of any psychiatric diagnosis (OR=5.3,  $p = 0.01$ ) and ADHD (OR=7.0,  $p = 0.02$ ) than controls. The prevalence of ASD in child carriers of deletions and duplications was similar (22% vs. 26%). Comparison of the two CNV groups indicated higher frequency of ADHD in children with the duplication than deletion (OR=2.7,  $p = 0.04$ ) as well as higher frequency of overall psychiatric disorders (OR=2.8,  $p = 0.02$ ) and psychotic symptoms (OR=4.7,  $p = 0.02$ ). However, no differences between deletion and duplications carriers in the prevalence of ASD were found. Both deletion and duplication are associated with increased risk of psychiatric disorder, supporting the importance of early recognition, diagnosis and intervention in these groups.

## Introduction

Copy number variations (CNVs) in 16p11.2 (deletion and duplication) between break points 4 and 5 (BP4-BP5) (600kb, chr16; 29.6-30.2 mb-HG19) occur at a frequency of ~3 in 10,000<sup>1</sup>. Around 71% of the 16p11.2 deletions occur *de novo* while the majority of the 16p11.2 duplications (70%) are familial<sup>2</sup>. This is consistent with the notion that 16p11.2 deletions have a greater impact on functioning, resulting in reduced fecundity<sup>3</sup>. Both 16p11.2 deletion and duplication have been associated with risk for Autism Spectrum Disorder (ASD). Evidence comes from studies of individuals with ASD<sup>4-11</sup> with a meta-analysis of 3,613 cases reporting a prevalence of 0.50% (95%CI: 0.31%-0.82%) for the 16p11.2 deletion and of 0.25% (96%CI: 0.14%-0.56%) for the duplication<sup>12</sup>. The 16p11.2 duplication, but not deletion, has been linked to risk of schizophrenia in a meta-analysis of 16,772 cases reporting a prevalence of 0.35% (95%CI:0.27%-0.45%) in cases compared to 0.03% in controls (95%CI:0.02%-0.05%)<sup>13</sup>. This has been supported by comparisons of schizophrenia patients and controls<sup>13</sup> and parent-proband trios<sup>14</sup>. The effect of these CNVs on mean IQ is a decrease of approximately two standard deviations for the deletion and one standard deviation for the duplication<sup>2, 15, 16</sup>. Apart from ASD, studies of 16p11.2 deletion carriers indicate high frequencies of Attention Deficit Hyperactivity Disorder (ADHD) (19%<sup>15</sup> to 38%<sup>17</sup>), anxiety disorders (6%<sup>15</sup> to 25%<sup>18</sup>), mood disorders (15%<sup>18</sup>), and Oppositional Defiant Disorder (ODD) and other disruptive disorders (13%<sup>15</sup> to 39%<sup>3</sup>). For carriers with the duplication, high rates of ADHD (30%<sup>3</sup>) have been reported.

Interestingly, these chromosomal rearrangements have been associated with mirrored physical phenotypic effects. The 16p11.2 deletion has been associated with risk of morbid obesity and large head circumference, while the 16p11.2 duplication has been associated with low body mass index (BMI) and small head circumference<sup>2, 18, 19</sup>. Taking into account evidence suggesting links between small head circumference and schizophrenia<sup>20, 21</sup> and large head circumference with autism<sup>22, 23</sup>, it has been suggested that these mirrored phenotypic effects (overgrowth versus undergrowth phenotype) extend to include psychopathology<sup>24</sup>, although this has not yet been formally evaluated. More specifically, it has been suggested that differences in gene

dosage associated with a single set of genes within 16p11.2 (deletion) versus three copies (duplication) may mediate risk of ASD versus schizophrenia<sup>25, 26</sup>. The 16p11.2 CNV has been presented as an example of this theory, such that deletion carriers may be at increased risk of ASD in particular, whilst duplication carriers are at risk of ASD and schizophrenia<sup>2, 18, 26</sup>.

Despite strong evidence that 16p11.2 deletions and duplications are associated with increased risk of psychiatric conditions, the majority of studies are based on limited and non-systematic assessments (e.g., medical records). Although informative, such records are less suited to systematic evaluation of large samples, because of differences between medical centers and clinicians in diagnostic methods used and clinical documentation. With the exception of schizophrenia and ASD, previous studies have been based on relatively small samples, without the availability of control samples to allow comparisons.

Here we report the largest study to date using detailed systematically performed psychiatric assessments to determine the nature and prevalence of psychopathology in children with deletion or duplication of 16p11.2. We hypothesized that children with 16p11.2 deletion and duplication have higher frequency of psychiatric disorder than family controls. We also hypothesized that deletion carriers would be more severely affected than duplication carriers, based on findings that the deletion is more likely to arise *de novo*, whereas the duplication is more frequently inherited. Finally, given the evidence that the 16p11.2 CNV is associated with a mirror phenotype of head and body size, we hypothesized that the children with 16p11.2 deletion have higher frequency of ASD compared to those with 16p11.2 duplication while children with 16p11.2 duplication have higher frequency of psychotic symptoms than those with 16p11.2 deletion.

## **Materials/Subjects and Methods**

### **Sample**

This study combined child samples (age <18 years old) recruited through Medical Genetics clinics and collected in Europe (EU) and the US (Table 1). The samples were provided from the ECHO study, the 16p11.2 European Consortium, the IMAGINE-ID study and the Simons VIP Consortium (Table 2). The sample characteristics of the ECHO study, 16p11.2 European Consortium and the Simons VIP Consortium have been described elsewhere<sup>2, 15</sup>. The study methodology and sample assessment of the UK ECHO study and IMAGINE-ID project are identical. A subset of these families (i.e., from the Simon's VIP cohort) has been described in prior studies in terms of their IQ, ASD and schizophrenia diagnoses<sup>2, 27</sup>.

Carrier status for the 16p11.2 deletion or duplication was confirmed for all individuals through clinical chromosome microarrays, medical records and/or confirmation in a research laboratory. All participants had a CNV in 16p11.2 BP4-BP5 region, excluding those in the adjacent region. Family members (siblings) who did not carry the CNV participated as family controls (controls) (Table 1). To assess potential recruitment bias in children, as a supplementary analysis, we further divided the carriers into a) probands (individuals who first came to the attention of medical services) and b) relative carriers (i.e., their siblings who were identified and diagnosed following CNV diagnosis of the proband) and compared the frequencies of psychiatric diagnoses between these two groups. Current analyses included individuals  $\geq 3$  years old in order to standardize diagnoses, especially for ASD, in very young children<sup>15</sup>.

The study was approved by the appropriate local ethics committees and institutional review boards. Each participant and his or her caregiver, when appropriate, provided informed written consent/assent to participate prior to recruitment.

### **Psychiatric assessments**

Assessments were performed using research diagnostic instruments as previously reported<sup>2</sup> under the supervision of experienced and licensed clinicians who gave best

estimate clinical and research DSM-IV-TR (Table 2). Only diagnoses that were available for all participating sites were examined. Only 2% of children with deletion and duplication were diagnosed with any syndromal psychotic disorder vs. 0% of controls. Therefore, psychotic symptoms were examined instead.

IQ scores have already been reported for this sample<sup>2</sup>. We present the full-scale IQ scores and comparisons of psychopathology for subgroups of carriers with and without intellectual disability (ID, as defined by IQ  $\leq$ 70).

### **Statistical Analysis**

Data analysis was conducted using Stata (version 13)<sup>28</sup>. Descriptive statistics were calculated to assess the frequency of psychiatric disorder. Random effects logit models were performed to determine whether group status (e.g., probands vs. controls) (independent variable) was associated with increased risk for psychiatric disorder (dependent variable: 0=no diagnosis, 1= diagnosis present) while accounting for familial clustering (i.e., the family that each individual belongs to). Odds ratios (ORs) and 95% confidence intervals (95% CIs) were derived and adjusted for age, sex and cohort status (i.e., EU vs. US)<sup>2</sup>. In cases where the maximum likelihood estimates tended to infinity (i.e., rare outcomes/ zero values), Firth's method<sup>29</sup> was used<sup>30</sup>. To assess recruitment bias, we repeated these analyses comparing probands vs. relative carriers. In order to reduce the number of statistical comparisons, anxiety disorders were included in the analyses as a summary variable (i.e., any anxiety disorder). We tested the associations between psychopathology and gender, inheritance status and ID using the phi coefficient.



## Results

Table 1 shows descriptive statistics of the sample by cohort status (i.e., EU and US).

### 1) Deletion carriers versus family controls

217 carriers and 77 controls were included in the analyses. 48% of the carriers met criteria for at least one psychiatric disorder (Table 3, S-Table 1, Figure 1). This prevalence was higher than for controls (17%, OR=8.9,  $p<0.001$ ). The most prevalent diagnosis in the carriers was ADHD (29%). This prevalence was higher than in controls (13%, OR=4.0,  $p=0.01$ ). ASD was the second most common diagnosis in carriers (22%), which was higher than in controls (0%, OR=39.9,  $p=0.01$ ). ID was also more frequent among carriers (30%) than controls (0%, OR=58.7,  $p=0.004$ ). No significant differences were found in the prevalence of anxiety disorders, ODD/CD, and psychotic symptoms in deletion carriers compared to controls. Male children with deletions were more likely than females to be diagnosed with any psychiatric disorder, ASD and ID, and individuals with inherited deletion were more likely to have ID (S-Table 2).

### 2) Duplication carriers versus family controls

114 carriers and 32 controls were included in the analyses. 63% of the carriers had at least one psychiatric disorder (Table 3, S-table 1, Figure 1). This frequency was higher than for controls (31%, OR=5.3,  $p=0.01$ , Table 3). ADHD was the most common diagnosis in the carriers (42%) and was elevated compared to controls (19%, OR=7.0,  $p=0.02$ ). There were no differences in the prevalence of anxiety disorders, ASD, ODD/CD and psychotic symptoms between carriers and controls. ID was higher in carriers (34%) than controls (3%, OR=56.7,  $p=0.03$ ). Males were more likely to be diagnosed with ODD/CD, and individuals with ID to be diagnosed with ASD (S-table 2).

### 3) Deletion versus duplication carriers

Duplication carriers had higher frequencies of any diagnosis (OR=2.8,  $p=0.02$ ), ADHD (OR=2.7,  $p=0.04$ ) and psychotic symptoms (OR=4.7,  $p=0.02$ ) than deletion carriers. No other differences were found (Table 3).

### 4) Assessment of potential recruitment bias

No differences were found between probands and relative carriers with the deletion in the prevalence of psychiatric disorders (S-table 3). However, probands with the duplication had higher frequencies of any psychiatric disorder than relative carriers (OR=3.9, p=0.01).

## Discussion

### Psychiatric disorders in children with 16p11.2 deletion and duplication

Our findings indicate that the mental health consequences of the 16p11.2 deletion and duplication are broad, similar to findings in other CNVs (e.g., 22q11.2 deletion syndrome<sup>31, 32</sup>).

ASD frequencies were higher in deletion carriers when compared to controls. In addition, almost half of the carriers with either the deletion or duplication were diagnosed with at least one psychiatric diagnosis, a frequency much higher than for non-carriers. This is similar to previously reported frequencies in medical records-based studies of individuals with 16p11.2 deletion<sup>33</sup> and duplication<sup>3</sup>. ADHD was the most commonly diagnosed disorder affecting between 30-40% of deletion and duplication carriers, similar to the frequencies previously reported<sup>3, 15, 17, 18</sup>. ID was present in about a third of deletion and duplication carriers and was also much more common than amongst controls. Frequency of anxiety and ODD/CD disorders and psychotic symptoms did not differ between carriers and controls, consistent with previous studies<sup>15, 18</sup>.

Previous studies in population based samples of CNV carriers have found high frequencies of cognitive impairments and psychiatric symptoms<sup>24, 34</sup>. This indicates that these high frequencies are not attributable to recruitment bias but are also representative of unselected CNV populations. Indeed, we generally did not find evidence of ascertainment bias effects on phenotypic assessment, as the frequencies of psychiatric diagnoses did not differ between probands and relative carriers. The only exception was our finding of higher frequencies of any psychiatric diagnoses in child duplication compared to relative carriers.

Although we found evidence for differences in the prevalence of psychotic symptoms, we did not find evidence for differences in the prevalence of ASD between 16p11.2 deletion and duplication carriers, for which we had more power. Thus, our findings do not provide support of a mirror phenotype for psychiatric disorder. More generally, both deletion and duplication showed significant and overlapping psychopathology and any

differences were of degree rather than suggesting contrasting mirror effects at the level of psychopathology.

Interestingly, we found associations between sex and any psychiatric disorder, ASD and ID in children with 16p11.2 deletion and ODD/CD in children with 16p11.2 duplication, indicating increased risk for males. No other associations were found with ADHD or psychotic symptoms which agrees with a previous study that examined questionnaire responses<sup>18</sup> as well as with findings related to another CNV on chromosome 22, resulting in 22q11.2 deletion syndrome<sup>32</sup>. These findings point to possible negation of sex-related burden to some psychiatric disorders by these CNVs<sup>35</sup>. Apart from an increased risk of ASD in children with 16p11.2 duplication, psychiatric disorders did not occur more frequently in participants with ID in children with 16p11.2 deletion or duplication. Although this could reflect insufficient power, it could also indicate that these CNVs have pleiotropic effects on IQ and psychopathology<sup>36</sup>. Finally, there was an association between inherited status and higher risk of ID indicating that potential parental genetic and environmental effects might be negatively implicated on child intelligence. There were no other associations with inheritance status and psychiatric diagnoses, similar to a previous study<sup>15</sup>.

### **Strengths and limitations**

This is the largest study to date to perform detailed phenotypic assessments on children with 16p11.2 deletion and duplication and compare the frequency of psychopathology with familial controls as well as between deletion and duplication carriers.

Our findings may be influenced by ascertainment bias. First, although we did not recruit individuals from psychiatric services, ascertainment was based on a phenotype significant enough to trigger clinical genetic testing (e.g., developmental delay). Second, although for many phenotypes we did not find evidence for recruitment bias in our analyses, we did find higher frequencies of any psychiatric diagnoses in child duplication probands compared to child relative carriers. We have previously explained our ascertainment strategies and limitations<sup>15, 32</sup>. It is noteworthy that there were relatively high frequencies of psychopathology in familial controls. 17% and 31% of non-carrier child relatives of individuals with deletion and duplication, respectively, met

criteria for at least one psychiatric diagnosis. The frequencies of ADHD (13% for deletion and 19% for duplication) and ASD (7% for duplication) were higher than we would expect from a population-based sample (5-7% and 1%, respectively). Potential explanations could be increased background environmental risk (e.g., the effect of family psychopathology), or perhaps the presence of polygenic or other additional genetic background effects that could also be a result of assortative mating.

Irrespective, our findings indicate that carriers of deletion or duplication of CNV at 16p11.2 who come to the attention of Medical Genetics services are at high risk of psychiatric disorder, and this is of importance for treating clinicians as well as the families themselves. If anything, our estimates represent an underestimate, given that the risks are elevated in our comparison sample of non-carrying familial controls.

Finally, the assessments at all sites were made by experienced clinicians and highly trained and clinically supervised psychologists. However, there were differences in the frequencies of psychiatric diagnoses and ID and although we adjusted for cohort status, we cannot exclude that potentially different diagnostic practices between the sites and countries in this study might have played a role in our findings. Further research is needed to examine psychopathology associated with these CNVs in population-based samples as well as to understand their longitudinal course.

### **Clinical implications and future directions**

This study clearly indicates that the phenotypic effects of the 16p11.2 deletion and duplication extend to include non-ASD psychopathology. The high frequency of psychiatric disorders, especially ADHD, in childhood indicate the need for recognition, diagnosis and treatment early in development. Longitudinal studies are needed to examine the natural history of these disorders and whether specific types of treatment (e.g., stimulant medication for ADHD) are beneficial<sup>37</sup>. Not all children met criteria for a psychiatric disorder, supporting previous literature indicating that there is a spectrum of manifestations of the 16p11.2 deletions and duplications<sup>7</sup>, similar to other CNVs (e.g., 22q11.2DS<sup>32</sup>).

Future studies could examine the extent to which assortative mating plays a role in psychiatric risk in children from families where a CNV is inherited compared to where it

occurs de novo. Further exploration of the extent to which background genetic as well as environmental risk factors contribute to risk of psychiatric disorder in carriers with a de novo versus an inherited CNV is also important.

### **Conclusions**

We examined the frequency of psychopathology in children with 16p11.2 deletion and duplication. Our findings indicate a high frequency of psychopathology compared to familial controls and suggest the importance of recognition, diagnosis and intervention in early development. The frequency of psychotic symptoms and ASD are similar in deletion and duplication carriers, indicating that mirrored physical effects of deletion and duplication do not extend to psychopathology.

### **Acknowledgements**

We are extremely grateful to all the families that participated in this study as well as to support charity Unique for their help and the research teams.

**Conflict of Interest Disclosures:** None reported.

**Funding:** This study was funded by the Wellcome Trust (110222/Z/15/Z)(MN), IMAGINE grant (MR/N022572/1, MR/L011166/1), DEFINE Wellcome Trust Strategic Award, Medical Research Council Centre grant (G0801418), Medical Research Council Programme Grant (G0800509), and the Simons Foundation (Simons VIP).

**Table 1.** Description of 16p11.2 cohort, carrier groups and controls

<b>Cohort by carrier group</b>	<b>Sample size</b>	<b>Male (%)</b>	<b>Age, mean(SD)</b>	<b>De Novo(%)</b>	<b>Inherited</b>
<b>16p11.2 deletion</b>					
<b>European</b>					
Carriers	101	65(64%)	9.5(3.1)	45(56%)	36(44%)
Controls	22	16(73%)	9.8(3.1)		
<b>United States</b>					
Carriers	116	61(53%)	8.5(3.3)	67(74%)	23(26%)
Controls	55	20(36%)	9.8(4.0)		
<b>16p11.2 duplication</b>					
<b>European</b>					
Carriers	46	30(65%)	9.0(3.3)	9(24%)	29(76%)
Controls	7	5(71%)	10.6(5.7)		
<b>United States</b>					
Carriers	68	35(52%)	8.1(3.7)	9(16%)	46(84%)
Controls	25	13(52%)	8.1(3.9)		
Notes: Counts of De Novo and Inherited do not add up to 100% because a number of carriers were of unknown status. Percentages are estimated not taking into account individuals with unknown status.					

**Table 2.** Measures used in the European and United States cohorts

<b>Cohort</b>	<b>Studies included</b>	<b>Measures</b>
European(EU)	ECHO	CAPA & ADI-R
	IMAGINE-ID	CAPA & ADI-R
	16p11.2 European Consortium	Clinical interviews & the Conners CBRS for children, ADI-R and ADOS
United States(US)	Simons VIP Consortium	DISC and clinical observations for all subjects in combinations with IQ testing and supporting measures (SCL-90, BAPQ, SRS), ADI-R and ADOS
<p><b>Abbreviations:</b> <b>ECHO</b> = the Cardiff University Experiences of people with copy number variants (ECHO) study (see <a href="http://medicine.cf.ac.uk/psychological-medicine-neuroscience/areas-research/copy-number-variant-research/research-projects/">http://medicine.cf.ac.uk/psychological-medicine-neuroscience/areas-research/copy-number-variant-research/research-projects/</a>), <b>IMAGINE-ID</b> = intellectual disability and mental health: assessing genomic impact on neurodevelopment (see: <a href="http://www.imagine-id.org/">http://www.imagine-id.org/</a>). <b>Simons VIP Consortium</b> = the Simons Variation in Individuals Project (VIP) Consortium (see <a href="https://www.simonsvipconnect.org/">https://www.simonsvipconnect.org/</a>). <b>CAPA</b> = Child and Adolescent Psychiatric Assessment (CAPA); <b>Conners CBRS</b> = Conners Comprehensive Behavior Rating Scales <sup>38</sup>; <b>DISC</b> = Diagnostic Interview Schedule for Children <sup>39</sup>; <b>ADI-R</b> = the Autism Diagnostic Interview – Revised <sup>40</sup>; <b>ADOS</b> = the Autism Diagnostic Observation Schedule <sup>40</sup>; <b>SCL-90</b> = Symptom Checklist – 90 <sup>41</sup>; <b>BAPQ</b> = Broad Autism Phenotype Questionnaire (Hurley, Losh et al. 2007); <b>SRS</b> = Social Responsiveness Scale <sup>42</sup>.</p>		



**Table 3.** Psychiatric diagnoses, psychotic symptoms and intellectual disability in children by 16p11.2 status

CHILDREN	Deletion			
	Carriers (N=217)	Controls (N= 77)	Odds ratio (95%CI)	p
	N(%)	N(%)		
<b>Any diagnosis</b>	<b>105(48)</b>	<b>13(17)</b>	<b>8.9(2.9-27.3)</b>	<b>p&lt;0.001</b>
<b>Any anxiety disorder</b>	20(9)	2(3)	3.0(0.7-13.4)	0.16
<b>ADHD</b>	<b>63(29)</b>	<b>10(13)</b>	<b>4.0(1.3-11.9)</b>	<b>0.01</b>
<b>ASD</b>	<b>41(22)</b>	<b>0(0)</b>	<b>39.9(2.4-660.5)</b>	<b>0.01</b>
<b>Psychotic symptoms</b>	5(4)	2(4)	0.6(0.1-2.7)	0.46
<b>ODD/CD</b>	15(7)	0(0)	9.3(0.5-159.2)	0.12
<b>ID*</b>	<b>61(30)</b>	<b>0(0)</b>	<b>58.7(3.5-973.1)</b>	<b>0.004</b>
	Duplication			
	Carriers (N=114)	Controls (N=32)	Odds ratio (95%CI)	p
	N(%)	N(%)		
<b>Any diagnosis</b>	<b>72(63)</b>	<b>10(31)</b>	<b>5.3(1.6-17.1)</b>	<b>0.01</b>
<b>Any anxiety disorder</b>	14(12)	1(3)	2.6(0.3-23.6)	0.38
<b>ADHD</b>	<b>48(42)</b>	<b>6(19)</b>	<b>7.0(1.4-35.9)</b>	<b>0.02</b>
<b>ASD</b>	26(26)	3(7)	4.5(0.7-27.3)	0.10
<b>Psychotic symptoms</b>	7(11)	0(0)	2.2(0.10-49.2)	0.61
<b>ODD/CD</b>	14(12)	1(3)	5.1(0.6-46.0)	0.14
<b>ID*</b>	<b>36(34)</b>	<b>1(3)</b>	<b>56.7(1.5-2193.2)</b>	<b>0.03</b>
	Duplication vs. deletion			
		Odds ratio (95%CI)		p
<b>Any diagnosis</b>		<b>2.8(1.2-6.7)</b>		<b>0.02</b>
<b>Any anxiety disorder</b>		2.0(0.9-4.5)		0.09
<b>ADHD</b>		<b>2.7(1.0-7.1)</b>		<b>0.04</b>
<b>ASD</b>		1.4(0.6-3.0)		0.44
<b>Psychotic symptoms</b>		<b>4.7(1.3-17.8)</b>		<b>0.02</b>
<b>ODD/CD</b>		2.1(1.0-4.7)		0.06
<b>ID*</b>		1.8(0.7-4.5)		0.19

**Notes:** Not all individuals had complete data on all diagnoses. Bold indicates p<0.05. ID was not included in the overall rates of 'any diagnosis'. The percentages represent the proportion of individuals with available diagnoses.

**Abbreviations:** ADHD=Attention Deficit Hyperactivity Disorder; ASD=Autism Spectrum Disorder; ODD/CD=Oppositional Defiant Disorder/Conduct Disorder. \* defined by IQ<=70

## References

1. Weiss LA, Shen Y, Korn JM, Arking DE, Miller DT, Fossdal R, et al. Association between microdeletion and microduplication at 16p11.2 and autism. *The New England journal of medicine*. 2008;358(7):667-675.
2. D'Angelo D, Lebon S, Chen Q, Martin-Brevet S, Snyder LG, Hippolyte L, et al. Defining the effect of the 16p11.2 duplication on cognition, behavior, and medical comorbidities. *JAMA psychiatry*. 2016;73(1):20-30.
3. Rosenfeld JA, Coppinger J, Bejjani BA, Girirajan S, Eichler EE, Shaffer LG, et al. Speech delays and behavioral problems are the predominant features in individuals with developmental delays and 16p11.2 microdeletions and microduplications. *Journal of neurodevelopmental disorders*. 2010;2(1):26-38.
4. Kumar RA, KaraMohamed S, Sudi J, Conrad DF, Brune C, Badner JA, et al. Recurrent 16p11.2 microdeletions in autism. *Human molecular genetics*. 2008;17(4):628-638.
5. Weiss LA, Shen Y, Korn JM, Arking DE, Miller DT, Fossdal R, et al. Association between microdeletion and microduplication at 16p11.2 and autism. *New England Journal of Medicine*. 2008;358(7):667-675.
6. Guilmatre A, Dubourg C, Mosca AL, Legallic S, Goldenberg A, Drouin-Garraud V, et al. Recurrent rearrangements in synaptic and neurodevelopmental genes and shared biologic pathways in schizophrenia, autism, and mental retardation. *Arch Gen Psychiatry*. 2009;66(9):947-956.
7. Glessner JT, Wang K, Cai G, Korvatska O, Kim CE, Wood S, et al. Autism genome-wide copy number variation reveals ubiquitin and neuronal genes. *Nature*. 2009;459(7246):569-573.
8. Marshall CR, Noor A, Vincent JB, Lionel AC, Feuk L, Skaug J, et al. Structural variation of chromosomes in autism spectrum disorder. *Am J Hum Genet*. 2008;82(2):477-488.
9. Sebat J, Lakshmi B, Malhotra D, Troge J, Lese-Martin C, Walsh T, et al. Strong Association of De Novo Copy Number Mutations with Autism. *Science*. 2007;316(5823):445-449.
10. van der Zwaag B, Franke L, Poot M, Hochstenbach R, Spierenburg HA, Vorstman JA, et al. Gene-network analysis identifies susceptibility genes related to glycobiology in autism. *PLoS One*. 2009;4(5):e5324.
11. Shen Y, Dies KA, Holm IA, Bridgemohan C, Sobeih MM, Caronna EB, et al. Clinical genetic testing for patients with autism spectrum disorders. *Pediatrics*. 2010;125(4):e727-735.
12. Walsh KM, Bracken MB. Copy number variation in the dosage-sensitive 16p11.2 interval accounts for only a small proportion of autism incidence: a systematic review and meta-analysis. *Genetics in medicine : official journal of the American College of Medical Genetics*. 2011;13(5):377-384.
13. Rees E, Walters JTR, Georgieva L, Isles AR, Chambert KD, Richards AL, et al. Analysis of copy number variations at 15 schizophrenia-associated loci. *The British Journal of Psychiatry*. 2013.
14. Kirov G, Pocklington AJ, Holmans P, Ivanov D, Ikeda M, Ruderfer D, et al. De novo CNV analysis implicates specific abnormalities of postsynaptic signalling

- complexes in the pathogenesis of schizophrenia. *Molecular psychiatry*. 2012;17(2):142-153.
15. Hanson E, Bernier R, Porche K, Jackson FI, Goin-Kochel RP, Snyder LG, et al. The Cognitive and Behavioral Phenotype of the 16p11.2 Deletion in a Clinically Ascertained Population. *Biological Psychiatry*. 2015;77(9):785-793.
  16. Hippolyte L, Maillard AM, Rodriguez-Herreros B, Pain A, Martin-Brevet S, Ferrari C, et al. The number of genomic copies at the 16p11.2 locus modulates language, verbal memory, and inhibition. *Biological psychiatry*. 2016;80(2):129-139.
  17. Shinawi M, Liu P, Kang SH, Shen J, Belmont JW, Scott DA, et al. Recurrent reciprocal 16p11.2 rearrangements associated with global developmental delay, behavioural problems, dysmorphism, epilepsy, and abnormal head size. *J Med Genet*. 2010;47(5):332-341.
  18. Zufferey F, Sherr EH, Beckmann ND, Hanson E, Maillard AM, Hippolyte L, et al. A 600 kb deletion syndrome at 16p11.2 leads to energy imbalance and neuropsychiatric disorders. *Journal of medical genetics*. 2012;49(10):660-668.
  19. Jacquemont S, Reymond A, Zufferey F, Harewood L, Walters RG, Kutalik Z, et al. Mirror extreme BMI phenotypes associated with gene dosage at the chromosome 16p11.2 locus. *Nature*. 2011;478(7367):97-102.
  20. Sacker A, Done DJ, Crow TJ. Obstetric complications in children born to parents with schizophrenia: a meta-analysis of case-control studies. *Psychol Med*. 1996;26(2):279-287.
  21. McNeil TF, Cantor-Graae E, Ismail B. Obstetric complications and congenital malformation in schizophrenia. *Brain Res Brain Res Rev*. 2000;31(2-3):166-178.
  22. Fidler DJ, Bailey JN, Smalley SL. Macrocephaly in autism and other pervasive developmental disorders. *Dev Med Child Neurol*. 2000;42(11):737-740.
  23. Gillberg C, De Souza L. Head circumference in autism, Asperger syndrome, and ADHD: a comparative study. *Developmental Medicine & Child Neurology*. 2002;44(05):296-300.
  24. Stefansson H, Meyer-Lindenberg A, Steinberg S, Magnusdottir B, Morgen K, Arnarsdottir S, et al. CNVs conferring risk of autism or schizophrenia affect cognition in controls. *Nature*. 2014;505(7483):361-366.
  25. Crespi B, Badcock C. Psychosis and autism as diametrical disorders of the social brain. *Behav Brain Sci*. 2008;31(3):241-261; discussion 261-320.
  26. Crespi B, Stead P, Elliot M. Comparative genomics of autism and schizophrenia. *Proceedings of the National Academy of Sciences*. 2010;107(suppl 1):1736-1741.
  27. Moreno-De-Luca A, Evans DW, Boomer K, Hanson E, Bernier R, Goin-Kochel RP, et al. The role of parental cognitive, behavioral, and motor profiles in clinical variability in individuals with chromosome 16p11.2 deletions. *JAMA psychiatry*. 2015;72(2):119-126.
  28. StataCorp. *Stata Statistical Software: Release 11*. In: Statacorp, editor. College Station, TX: Statcorp LP; 2009.
  29. Firth D. Bias reduction of maximum likelihood estimates. *Biometrika*. 1993;80(1):27-38.
  30. Heinze G, Schemper M. A solution to the problem of separation in logistic regression. *Statistics in medicine*. 2002;21(16):2409-2419.

31. Schneider M, Debbane M, Bassett AS, Chow EW, Fung WL, van den Bree M, et al. Psychiatric disorders from childhood to adulthood in 22q11.2 deletion syndrome: results from the International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome. *Am J Psychiatry*. 2014;171(6):627-639.
32. Niarchou M, Zammit S, van Goozen SH, Thapar A, Tierling HM, Owen MJ, et al. Psychopathology and cognition in children with 22q11.2 deletion syndrome. *Br J Psychiatry*. 2014;204(1):46-54.
33. Hanson E, Nasir RH, Fong A, Lian A, Hundley R, Shen Y, et al. Cognitive and behavioral characterization of 16p11.2 deletion syndrome. *J Dev Behav Pediatr*. 2010;31(8):649-657.
34. Männik K, Mägi R, Macé A, et al. Copy number variations and cognitive phenotypes in unselected populations. *JAMA*. 2015;313(20):2044-2054.
35. Niarchou M, Martin J, Thapar A, Owen MJ, van den Bree M. The clinical presentation of attention deficit-hyperactivity disorder (ADHD) in children with 22q11.2 deletion syndrome. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*. 2015.
36. O'Donovan MC, Kirov G, Owen MJ. Phenotypic variations on the theme of CNVs. *Nat Genet*. 2008;40(12):1392-1393.
37. Gothelf D, Gruber R, Presburger G, Dotan I, Brand-Gothelf A, Burg M, et al. Methylphenidate treatment for attention-deficit/hyperactivity disorder in children and adolescents with velocardiofacial syndrome: an open-label study. *J Clin Psychiatry*. 2003;64(10):1163-1169.
38. Goyette CH, Conners CK, Ulrich RF. Normative data on revised Conners parent and teacher rating scales. *Journal of abnormal child psychology*. 1978;6(2):221-236.
39. Shaffer D, Fisher P, Lucas CP, Dulcan MK, Schwab-Stone ME. NIMH Diagnostic Interview Schedule for Children Version IV (NIMH DISC-IV): description, differences from previous versions, and reliability of some common diagnoses. *J Am Acad Child Adolesc Psychiatry*. 2000;39(1):28-38.
40. Lord C, Rutter M, Couteur A. Autism Diagnostic Interview-Revised: A revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. *Journal of Autism and Developmental Disorders*. 1994;24(5):659-685.
41. Derogatis LR, Lipman RS, Covi L. SCL-90: An outpatient psychiatric rating scale - preliminary report. *Psychopharmacological Bulletin*. 1973;9:13-28.
42. Constantino JN, Davis SA, Todd RD, Schindler MK, Gross MM, Brophy SL, et al. Validation of a brief quantitative measure of autistic traits: comparison of the social responsiveness scale with the autism diagnostic interview-revised. *Journal of autism and developmental disorders*. 2003;33(4):427-433.

**S-Table 1.** Psychiatric diagnoses, psychotic symptoms and intellectual disability in children by 16p11.2 status, cohort and carrier group

CHILDREN	16p11.2 deletion						16p11.2 duplication					
	Europe			United States			Europe			United States		
	Carriers	Carrier relatives	Controls	Carriers	Carrier relatives	Controls	Carriers	Carrier relatives	Controls	Carriers	Carrier relatives	Controls
N	87	14	22	106	10	55	39	7	7	50	18	25
	Mean(SD)	Mean(SD)	Mean(SD)	Mean(SD)	Mean(SD)	Mean(SD)	Mean(SD)	Mean(SD)	Mean(SD)	Mean(SD)	Mean(SD)	Mean(SD)
IQ	73.8(14.1)	69.6(14.1)	99.2(12.6)	84.6(15.8)	81.3(16.4)	106.8(9.8)	67.5(21.9)	79(20.6)	103(18.2)	77.2(21.4)	85.9(17.8)	100.7(19.7)
	N(%)	N(%)	N(%)	N(%)	N(%)	N(%)	N(%)	N(%)	N(%)	N(%)	%(N)	N(%)
Intellectual disability*	31(41)	8(57)	0(0)	20(19)	2(22)	0(0)	15(44)	2(33)	0(0)	16(33)	3(17)	1(4)
Any diagnosis	41(47)	4(29)	3(15)	57(54)	3(30)	10(18)	29(74)	4(57)	2(29)	33(66)	6(33)	8(32)
Any anxiety disorder	13(15)	2(14)	0(0)	5(5)	0(0)	2(4)	7(18)	3(43)	0(0)	3(6)	1(6)	1(4)
Specific phobia	3(3)	0(0)	0(0)	0(0)	0(0)	0(0)	4(10)	1(14)	0(0)	1(2)	0(0)	0(0)
Social Phobia	9(10)	0(0)	0(0)	1(1)	0(0)	0(0)	1(3)	2(29)	0(0)	0(0)	0(0)	1(4)
SAD	4(5)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	1(14)	0(0)	0(0)	0(0)	0(0)
Agoraphobia	4(5)	1(7)	0(0)	0(0)	0(0)	0(0)	2(5)	1(14)	0(0)	0(0)	0(0)	0(0)
OCD	2(2)	1(7)	0(0)	0(0)	0(0)	0(0)	0(0)	1(14)	0(0)	2(4)	0(0)	0(0)
GAD	2(2)	1(7)	0(0)	4(4)	0(0)	2(4)	6(15)	2(29)	0(0)	0(0)	1(6)	0(0)
MDD	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)
Dysthymic disorder	1(1)	0(0)	0(0)	0(0)	0(0)	1(2)	1(3)	0(0)	0(0)	1(2)	0(0)	0(0)
ADHD	27(31)	3(21)	3(15)	32(30)	1(10)	7(13)	15(38)	4(57)	2(29)	24(48)	5(28)	4(16)
ASD	12(19)	0(0)	0(0)	27(25)	2(20)	0(0)	12(43)	0(0)	0(0)	12(24)	2(11)	3(12)
ODD/CD	7(8)	2(14)	0(0)	6(6)	0(0)	0(0)	4(10)	3(43)	0(0)	7(14)	0(0)	1(4)
Psychotic symptoms	5(10)	0(0)	2(13)	0(0)	0(0)	0(0)	6(40)	0(0)	0(0)	1(3)	0(0)	0(0)
Any psychosis	0(0)	0(0)	0(0)	4(4)	0(0)	0(0)	1(3)	0(0)	0(0)	0(0)	1(6)	0(0)
Schizophrenia	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	1(6)	0(0)
Substance/alc ohol abuse	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	1(3)	0(0)	0(0)	0(0)	0(0)	0(0)

Abbreviations: SAD=Separation Anxiety Disorder; OCD=Obsessive Compulsive Disorder; GAD=Generalized Anxiety Disorder; MDD=Major Depressive Disorder; ADHD=Attention Deficit Hyperactivity Disorder; ASD=Autism Spectrum Disorder; ODD/CD=Oppositional Defiant Disorder/Conduct Disorder. \* defined by IQ<=70 \*\* no ASD diagnosis available


**S-Table 2.** Relationship between sex, inheritance and intellectual disability with psychopathology in children with 16p11.2 deletion and duplication

CHILDREN			
16p11.2 deletion			
Diagnosis	Males/Females	Inheritance (de novo/inherited)	Intellectual disability* (No/Yes)
Intellectual disability	<b>-0.15 (p=0.03)</b>	<b>0.19 (p=0.01)</b>	
Any diagnosis	<b>-0.13(p=0.05)</b>	-0.13	0.08
Any anxiety disorder	-0.05	0.04	0.07
ADHD	-0.05	-0.09	0.02
ODD/CD	-0.05	-0.11	0.12
Psychotic symptoms	-0.09	0.08	-0.02
ASD	<b>-0.16(p=0.03)</b>	-0.16	0.05
16p11.2 duplication			
Diagnosis	Males/Females	Inheritance (inherited/de novo)	Intellectual disability*
Intellectual disability	0.05	-0.04	
Any diagnosis	-0.15	-0.18	0.10
Any anxiety disorder	-0.00	0.07	-0.20(p=0.03)
ADHD	-0.06	-0.10	-0.18
ODD/CD	<b>-0.22(p=0.02)</b>	0.19	-0.13
Psychotic symptoms	0.18	0.10	-0.04
ASD	-0.10	-0.11	<b>0.45(p&lt;0.001)</b>
<p>In bold significant associations with p&lt;0.05. Negative associations signify that males/inherited/no intellectual disability are at greater risk.  Abbreviations: ADHD=Attention Deficit Hyperactivity Disorder, ODD/CD=Oppositional Defiant Disorder/Conduct Disorder, ASD=Autism Spectrum Disorder, MDD=Major Depressive Disorder  * defined by IQ&lt;=70</p>			

**S-Table 3.** Assessing recruitment bias.

CHILDREN	Any diagnoses		Any anxiety		ADHD		ODD/CD		Psychotic symptoms		ASD	
Comparisons	OR(95%CI)	p	OR(95%CI)	p	OR(95%CI)	p	OR(95%CI)	p	OR(95%CI)	p	OR(95%CI)	p
<b>Deletion</b>												
Probands vs. <i>relative carriers</i>	2.7(0.7-10.9)	0.17	1.1(0.2-5.7)	0.87	2.9(0.4-20.3)	0.29	0.8(0.2-3.7)	0.76	1.1(0.0-25.6)	0.97	2.7(0.4-16.2)	0.37
<b>Duplication</b>												
Probands vs. <i>relative carriers</i>	<b>3.9(1.3-11.5)</b>	<b>0.01</b>	0.4(0.1-1.8)	0.21	1.5(0.4-5.2)	0.50	0.7(0.2-3.2)	0.66	7.9(0.3-196.1)	0.21	4.0(0.8-18.7)	0.08
ORs adjusted for cohort, age and sex; Reference group is in italics; ASD=Autism Spectrum Disorder, ADHD=Attention Deficit Hyperactivity Disorder, ODD/CD=Oppositional Defiant Disorder/Conduct Disorder, ASD=Autism Spectrum Disorder												

Figure 1. Frequency of psychiatric diagnoses, psychotic symptoms and intellectual disability in children with 16p11.2 deletion and duplication



Abbreviations: ADHD=Attention Deficit Hyperactivity Disorder, ASD=Autism Spectrum Disorder, ID=Intellectual Disability, ODD/CD=Oppositional Defiant Disorder/Conduct Disorder, PS=Psychotic symptoms